Background
Methods
Tissue samples and chemicals
Isolation of placental villous trophoblast cells
Cell culture
Multiplex assays of cytokines in conditioned media
Immunocytochemistry
Western blotting
Quantitative real time RT-PCR
Data analysis
Enrichment analysis
Results
Profiles of secreted cyto/chemokines
Cytokine (Alias) | Concentration (ng/ml) of AMA applied | ||||
---|---|---|---|---|---|
0 | 1 | 10 | 100 | 1000 | |
CCL2 (MCP1) | 96.8 (3.2) | 80.8 (10.2) | 78.7 (14.6) | 73.1** (5.2) | 74.5** (5.9) |
CCL3 (MIP1Α) | 49.0 (2.9) | 53.2 (5.2) | 53.3 (5.2) | 44.4 (3.4) | 38.5* (2.1) |
CCL4 (MIP1B) | 298.0 (22.1) | 298.3 (12.9) | 350.6 (35.2) | 265.2* (12.6) | 260.2** (12.4) |
CCL5 (RANTES) | 362.4 (20.7) | 367.9 (30.3) | 362.4 (21.3) | 332.0* (17.9) | 309.7* (11.6) |
CLEC11A (SCGFB) | 592.1 (58.9) | 602.9 (72.0) | 609.3 (94.9) | 559.7 (68.7) | 544.9 (68.4) |
CXCL1 (GROΑ) | 678.0 (61.2) | 688.5 (22.9) | 649.2 (33.4) | 529.4** (29.3) | 527.2** (30.6) |
CXCL9 (MIG) | 113.2 (10.4) | 112.9 (16.0) | 114.2 (12.6) | 97.1 (15.4) | 99.4 (17.9) |
CXCL10 (IP-10) | 152.7 (12.5) | 143.7 (14.2) | 119.5 (28.0) | 129.9 (29.9) | 155.21 (10.74) |
CXCL12 (SDF-1) | 87.5 (14.1) | 89.6 (26.7) | 99. 9 (27.5) | 83.8 (13.3) | 79.6 (23.5) |
FGF2 (basic FGF) | 4.4 (0.3) | 4.9 (0.2) | 4.8 (0.2) | 4.1 (0.9) | 3.2* (0.5) |
GCSF (CSF-3) | 2307.5 (101.6) | 2260.1 (138.4) | 2242.3 (160.1) | 2127.0 (177.3) | 1946.0 (250.6) |
HGF (SF) | 12501.5 (1648.7) | 10638.3 (1955.3) | 10935.2 (1194.5) | 9930.7 (874.5) | 9920.1 (834.8) |
IFNA2 | 4.9 (1.9) | 11.1 (5.4) | 4.5 (0.9) | 4.9 (2.9) | 4.7 (1.6) |
IL1A | 113.4 (14.9) | 106.0(15.5) | 112.8 (17.0) | 128.7 (18.2) | 120.6 (13.4) |
IL1B | 353.0 (23.4) | 333.1 (34.2) | 322.7 (31.6) | 313.5* (26.9) | 302.2** (10.6) |
IL-1RA | 32.9 (2.6) | 30.2 (6.1) | 27.8 (6.5) | 29.5 (1.0) | 28.8 (3.0) |
IL-2RA (CD25) | ND | ND | 2.3
(i)
(0.1) | 2.2
(i)
(0.1) | 2.9
(i)
(0.2) |
IL6 (IFNΒ2) | 752.7 (41.8) | 736.2 (40.1) | 704.3 (31.3) | 611.5** (22.6) | 587.8** (26.1) |
IL8 (CXCL8) | 11779.0 (2146.6) | 12706.4 (2868.5) | 16701.7 (4785.2) | 14902.2 (4615.2) | 8302.9* (2435.9) |
IL9 (HP40) | 0.6 (0.3) | 0.3 (0.2) | 0.3 (0.2) | 0.4 (0.2) | 0.3 (0.2) |
IL16 (LCF) | 11.4(3.9) | 11.0 (4.8) | 18.7* (2.4) | 18.3* (2.6) | 18.8* (2.2) |
IL18 (IGIF) | 28.9 (2.8) | 30.2 (2.3) | 28.0 (3.0) | 25.2 (1.7) | 29.2 (1.7) |
LIF (DIA) | 2.8 (1.2) | 2.9 (1.4) | 2.9 (1.3) | 2.8 (1.2) | 3.1 (1.3) |
MCSF (CSF1) | 174.2 (16.2) | 125.9* (23.6) | 123.7* (21.3) | 121.6* (27.9) | 125.6** (7.4) |
MIF (MMIF) | 2919.2 (178.5) | 2790.7 (211.2) | 2708.6 (260.7) | 2231.1* (261.3) | 2154.2** (143.1) |
TNF (TNF alpha) | 0.6 (0.3) | 0.5 (0.2) | 0.4 (0.2) | 0.4 (0.2) | 0.4 (0.3) |
VEGF-A (VPF) | 0.3 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) |
Differential cyto/chemokine secretion profile following AMA administration
Steady state transcript levels of differentially secreted cytokines
Name of cytokine | Mean ± SD (n = 5/ea) | |||
---|---|---|---|---|
Concentration in conditioned mediuma
| Relative level of transcript in cellsb
| |||
Control | AMA | Control | AMA | |
CCL4 (MIP1B) | 298.0 | 260.2** | 2.5 | 2.6 |
±22.1 | ±12.4 | ±0.7 | ±0.9 | |
CCL5 (RANTES) | 362.4 | 309.7* | 5.2 | 5.8 |
±20.7 | ±11.6 | ±2.7 | ±2.1 | |
IL1A | 113.4 | 120.6 | 2.9 | 3.6 |
±14.9 | ±13.4 | ±2.4 | ±2.1 | |
IL1B | 353.0 | 302.2** | 2.5 | 2.9 |
±23.4 | ±10.6 | ±1.1 | ±1.5 | |
IL-2RA | 0.08c
| 2.9*** | 7.3 | 9.5** |
±0.03 | ±0.1 | ±0.1 | ±0.3 | |
IL6 | 752.7 | 587.8** | 5.8 | 6.9 |
±41.8 | ±21.1 | ±1.2 | ±1.8 | |
IL16 | 11.4 | 18.8* | 7.5 | 8.8** |
±3.9 | ±2.2 | ±0.1 | ±0.2 | |
MIF | 2919.2 | 2154.2 | 9.8 | 8.3* |
±178.5 | ±143.0 | ±0.6 | ±0.4 | |
TNF | 0.6 | 0.4 | 3.0 | 3.1 |
±0.3 | ±0.3 | ±0.5 | ±0.8 |
Analysis | Description of the process (p value) | Candidatesd
|
---|---|---|
Gene ontology (GO) cellular processa
| Inflammatory response (5.9E-12) |
CCL3, CCL4, CCL5, CXCL1, IL1A, IL1B, IL6, IL9, IL18, IL-1RA, IL-2RA, CXCL9, CXCL10, MIF, TNF |
Immune response (6.3E-12) |
CCL3, CCL4, CCL5, G-CSF, CXCL1, CXCL10, IL1A, IL1B, IL6, IL9, IL18, IL1RA, IL-2RA, LIF, MIF, TNF, VEGF | |
Regulation of cell proliferation (6.3E-12) |
CCL3, CCL4, CCL5, HGF, GCSF, CXCL1, CXCL9, CXCL10, IL1A, IL1B, IL6, IL9, IL18, IL-1RA, IL-2RA, LIF, MIF, TNF, VEGF | |
Response to wound healing (6.4E-12) |
CCL3, CCL4, CCL5, CXCL1, CXCL9, CXCL10, HGF, IL1A, IL1B, IL6, IL9, IL18, IL-1RA, MIF, TNF, VEGF | |
Cell chemotaxis (6.5E-12) | CLEC11A, CCL4, CCL5, CXCL1, CXCL9, CXCL10, HGF, IL1B, IL6, IL-2RA, VEGF | |
Enrichment by pathways mapb
| Cyto/chemokines in inflammation (3.8E-12) |
CCL4, CCL5, CXCL10, IL1A, IL1B, IL6, IL9, TNF |
Secreted signals in immune response (3.9E-12) |
CCL4, CCL5, CXCL10, IL1A, IL1B, IL-1RA, IL- 2RA, IL6, IL9, TNF | |
Most relevant networkc
| Toll-like receptor signaling pathway (2.3E-12) | IL1A, IL1B, ΙL6, MIF, TNF |